Cara Therapeutics reported $-27911000 in EBIT for its first fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebit Change
Acadia Pharmaceuticals ACAD:US $ -113016000 68.36M
Acelrx Pharmaceuticals ACRX:US $ -8995000 820K
Aerie Pharmaceuticals AERI:US $ -33643000 85.38M
Cara Therapeutics CARA:US $ -27911000 5.61M
Chugai Pharma 4519:JP 187.01B 47.94B
Endo International Ordinary Shares ENDP:US $ 120.25M 52.02M
Halozyme Therapeutics HALO:US $ 75.67M 19.14M
Horizon Pharma HZNP:US 196.44M 99.18M
JAZZ PHA JAZZ:US 87.55M 105.43M
Johnson & Johnson JNJ:US $ 7540M 1623M
Neurocrine Biosciences NBIX:US $ 3.1M 60.9M
Pacira Pharmaceuticals PCRX:US $ 21.73M 24.09M
Pain Therapeutics PTIE:US $ -17821000 3.38M
Pfizer PFE:US $ 9995M 4136M
Revance Therapeutics RVNC:US $ -62221000 617K
Supernus Pharmaceuticals SUPN:US $ 1.97M 26.43M
Teva Pharmaceutical Industries TEVA:US 789M 182M
Vanda Pharmaceuticals VNDA:US $ -7669000 36.1M